D-penicillamine and its effects on angiostatin generation and tumor growth
Author Information
Author(s): de Groot-Besseling Renate RJ, Ruers Theo JM, Lamers-Elemans Iris L, Maass Cathy N, de Waal Robert MW, Westphal Johan R
Primary Institution: University Medical Centre Nijmegen
Hypothesis
Can D-penicillamine enhance angiostatin generation and anti-tumor effects when combined with plasminogen activators?
Conclusion
D-penicillamine is not suitable for anti-angiogenic therapy as it did not effectively enhance angiostatin generation or anti-tumor effects in vivo.
Supporting Evidence
- D-penicillamine showed superior angiostatin generation in vitro but not in vivo.
- Combination treatment with D-penicillamine and tPA did not significantly enhance angiostatin levels.
- Treatment with tPA alone resulted in a greater reduction in tumor growth compared to D-penicillamine alone.
Takeaway
This study looked at a medicine called D-penicillamine to see if it could help fight tumors by making a substance called angiostatin. It turns out it didn't work as well in real mice as it did in lab tests.
Methodology
The study involved in vitro tests on angiostatin generation and in vivo tests on tumor growth in mice using D-penicillamine and plasminogen activators.
Potential Biases
Potential bias in the selection of free sulfhydryl donors and their effects on angiostatin generation.
Limitations
The study's findings may not be applicable to clinical settings due to differences between in vitro and in vivo results.
Participant Demographics
Healthy BALB/c mice were used for the in vivo experiments.
Statistical Information
P-Value
0.08
Statistical Significance
p = 0.08
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website